Effect of Autogenic Relaxation Therapy on Caregivers on Perceived Stress Quality of Life and Caregiver Burden

What Was Tested

In this not phased trial, researchers set out to test Relaxin (Serelaxin).

Caregivers are also faced with multiple stress factors.

Autogenic relaxation therapy will help caregivers relax and take time for themselves by getting away from the stressful life they have lived.

Although there are various studies on this subject (Chegeni et al. 2018, Seo and Kim 2019, Ramiraz-Garcia et al. 2020, Wang et al. 2021, Bagheri et all 2021, Ozhanlı and Akyuz 2022), there is no study on caregivers as far as the researchers could reach.

It had two arms (groups): intervention (experimental) and control (other).

The registry classes the interventions as behavioral and other.

Who Took Part

Enrollment: 64 planned participants were the target.

It was open to women only aged from 18 years up to 89 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Being over 18 years old. Being able to answer data collection forms. Being able to speak Turkish. Being able to provide continuous or partial care to a patient for at least 3 months. Being able to communicate.

The full record lists 5 inclusion and 7 exclusion criteria; among the exclusions: having epilepsy; not speaking or understanding turkish; having a neurological disability.

How the Study Was Run

It was run as a randomized, parallel-group and single-blind study.

Random assignment meant chance, not the researchers, decided who got Relaxin (Serelaxin) and who got the comparison, which limits bias.

The Relaxin (Serelaxin) group and the comparison group ran side by side rather than switching.

Only one side, usually the participants, was kept unaware of whether Relaxin (Serelaxin) was given.

Those kept unaware of assignments: participant.

It started in 2024-11-07 with completion listed for 2024-11-30.

It ran at 1 site in Turkey (Türkiye).

Its stated primary purpose is supportive care.

What Was Measured

Researchers chose this as the main measure: Principial (time frame: 1 month).

It also tracked 1 secondary outcome, for example second.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Relaxin (Serelaxin) in 64 people.

Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Relaxin (Serelaxin) compound page, all human trials.